SBFM
Sunshine Biopharma, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · CA
$1.14
+2.70%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 35.3M | 36.3M | 34.9M | 24.1M | 4.3M |
| Cost of Revenue | 24.8M | 24.4M | 24.2M | 15.8M | 2.6M |
| Gross Profit | 10.5M | 11.9M | 10.7M | 8.3M | 1.7M |
| Operating Expenses | |||||
| R&D Expense | (366.6K) | 604.3K | 933.9K | 1.9M | 811.9K |
| SG&A Expense | 19.2M | 19.6M | 14.9M | 10.8M | 9.5M |
| General & Admin Expense | 15.2M | 18.5M | 14.0M | 10.1M | 8.9M |
| Selling & Marketing Expense | 753.2K | 1.1M | 940.3K | 734.2K | 578.1K |
| Other Expenses | (3.1M) | (3.8M) | 610.5K | 438.9K | 80.4K |
| Total Operating Expenses | 15.7M | 16.4M | 16.5M | 13.1M | 10.4M |
| Cost and Expenses | 40.5M | 40.8M | 40.7M | 28.9M | 13.0M |
| Operating Income (EBIT) | (5.2M) | (4.5M) | (5.8M) | (4.8M) | (8.7M) |
| Non-Operating | |||||
| Interest Income | 230.1K | 280.9K | 496.0K | 812.0K | 518.6K |
| Interest Expense | — | — | 8.8K | 137.3K | 39.4K |
| Net Interest Income | 230.1K | 280.9K | 487.2K | 674.7K | 479.2K |
| Other Non-Op Income/Expense | (363.1K) | (1.5M) | 443.1K | 674.4K | (17.8M) |
| Non-Operating Income (excl Interest) | 411.8K | 1.5M | (451.9K) | (811.7K) | 17.8M |
| EBT (Pre-Tax Income) | (5.6M) | (6.0M) | (5.4M) | (4.1M) | (26.5M) |
| Income Tax Expense | 270.9K | 21.6K | (234.9K) | 395.2K | 233.3K |
| Bottom Line | |||||
| Net Income | (5.8M) | (6.0M) | (5.1M) | (4.5M) | (26.7M) |
| Earnings from Cont. Ops | (5.8M) | (6.0M) | (5.1M) | (4.5M) | (26.7M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (5.8M) | (6.0M) | (5.1M) | (4.5M) | (26.7M) |
| Per Share | |||||
| Basic EPS | ($10.15) | ($14.40) | ($73.20) | ($3,513.60) | ($35,236.40) |
| Diluted EPS | ($10.15) | ($14.40) | ($73.20) | ($3,513.60) | ($35,236.40) |
| Revenue Per Share | $25.89 | $87.33 | $496.96 | $19,796.87 | $5,725.43 |
| Shares | |||||
| Basic Shares Outstanding | 1.4M | 415709 | 70175 | 1217 | 759 |
| Diluted Shares Outstanding | 1.4M | 415709 | 70175 | 1217 | 759 |
| Profitability Metrics | |||||
| EBITDA | (5.3M) | (5.6M) | (5.1M) | (3.8M) | (26.4M) |
| D&A | 349.6K | 332.1K | 223.5K | 149.1K | 25.2K |
| EBIT | (5.6M) | (6.0M) | (5.4M) | (4.0M) | (26.5M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026